Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery

BioArctic, a Swedish biotechnology company renowned for its innovative approach to neurodegenerative diseases, has made significant strides in Alzheimer’s research. The company’s groundbreaking drug, Leqembi, developed in collaboration with Eisai, was the first to demonstrate a slowing of Alzheimer’s disease progression. Despite this success, a formidable challenge persists in the realm of neurological therapeutics: the blood-brain barrier (BBB). This selective barrier protects the brain from harmful substances but also impedes the delivery of potentially beneficial drugs. Addressing this obstacle, BioArctic has developed the BrainTransporter technology, designed to facilitate the passage of therapeutic agents across the BBB. This article delves into the intricacies of the BBB,

 » Read More